TECENTRIQ (ATEZOLIZUMAB)

1,200 mg/20 mL (60 mg/mL) intravenous solution

• Infuse 1,200 mg over 60 minute(s) by intravenous route every 3 weeks

840 mg/14 mL (60 mg/mL) intravenous solution

• Infuse 840 mg over 60 minute(s) by intravenous route on days 1 and 15Of a 28 day treatment cycle

HR negative, HEr2 negative, Pd-l1 positive breast cancer

• Infuse 840 mg over 60 minute(s) by intravenous route on days 1 and 15Of a 28 day treatment cycle

• Infuse 840 mg over 30 minute(s) by intravenous route on days 1 and 15Of a 28 day treatment cycle

Non-small cell lung cancer

• Infuse 1,200 mg over 60 minute(s) by intravenous route every 3 weeks

• Infuse 1,200 mg over 30 minute(s) by intravenous route every 3 weeks

• Infuse 1,680 mg over 60 minute(s) by intravenous route every 4 weeks

• Infuse 1,680 mg over 30 minute(s) by intravenous route every 4 weeks

Small cell lung carcinoma

• Infuse 1,200 mg over 60 minute(s) by intravenous route every 3 weeks

• Infuse 1,200 mg over 30 minute(s) by intravenous route every 3 weeks

• Infuse 1,680 mg over 60 minute(s) by intravenous route every 4 weeks

• Infuse 1,680 mg over 30 minute(s) by intravenous route every 4 weeks

Transitional cell carcinoma of the urinary tract

• Infuse 1,200 mg over 60 minute(s) by intravenous route every 3 weeks

• Infuse 1,200 mg over 30 minute(s) by intravenous route every 3 weeks

• Infuse 1,680 mg over 60 minute(s) by intravenous route every 4 weeks

• Infuse 1,680 mg over 30 minute(s) by intravenous route every 4 weeks